Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes

被引:11
|
作者
McPhail, Brooks [1 ]
Tie, Yunfeng [1 ]
Hong, Huixiao [2 ]
Pearce, Bruce A. [2 ]
Schnackenberg, Laura K. [2 ]
Ge, Weigong [2 ]
Valerio, Luis G., Jr. [3 ]
Fuscoe, James C. [2 ]
Tong, Weida [2 ]
Buzatu, Dan A. [2 ]
Wilkes, Jon G. [2 ]
Fowler, Bruce A. [1 ]
Demchuk, Eugene [1 ,4 ]
Beger, Richard D. [2 ]
机构
[1] Agcy Tox Subst & Dis Registry, Div Toxicol & Environm Med, Atlanta, GA 30333 USA
[2] US FDA, Div Syst Biol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
[3] US FDA, Sci & Res Staff, Off Pharmaceut Sci, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
[4] W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA
来源
MOLECULES | 2012年 / 17卷 / 03期
关键词
structure-activity relationship; SAR; SDAR; classifier; cytochrome P450; inhibitor; CYP3A4; CYP2D6; DRUG-DRUG INTERACTIONS; ANALYSIS COSCOSA MODELS; C-13; NMR; GENETIC POLYMORPHISMS; SPECTROMETRIC DATA; MOLECULAR DOCKING; KINETIC-ANALYSIS; DECISION FOREST; 3A4; BINDING;
D O I
10.3390/molecules17033383
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An interagency collaboration was established to model chemical interactions that may cause adverse health effects when an exposure to a mixture of chemicals occurs. Many of these chemicals-drugs, pesticides, and environmental pollutants-interact at the level of metabolic biotransformations mediated by cytochrome P450 (CYP) enzymes. In the present work, spectral data-activity relationship (SDAR) and structure- activity relationship (SAR) approaches were used to develop machine-learning classifiers of inhibitors and non-inhibitors of the CYP3A4 and CYP2D6 isozymes. The models were built upon 602 reference pharmaceutical compounds whose interactions have been deduced from clinical data, and 100 additional chemicals that were used to evaluate model performance in an external validation (EV) test. SDAR is an innovative modeling approach that relies on discriminant analysis applied to binned nuclear magnetic resonance (NMR) spectral descriptors. In the present work, both 1D C-13 and 1D N-15-NMR spectra were used together in a novel implementation of the SDAR technique. It was found that increasing the binning size of 1D C-13-NMR and N-15-NMR spectra caused an increase in the tenfold cross-validation (CV) performance in terms of both the rate of correct classification and sensitivity. The results of SDAR modeling were verified using SAR. For SAR modeling, a decision forest approach involving from 6 to 17 Mold(2) descriptors in a tree was used. Average rates of correct classification of SDAR and SAR models in a hundred CV tests were 60% and 61% for CYP3A4, and 62% and 70% for CYP2D6, respectively. The rates of correct classification of SDAR and SAR models in the EV test were 73% and 86% for CYP3A4, and 76% and 90% for CYP2D6, respectively. Thus, both SDAR and SAR methods demonstrated a comparable performance in modeling a large set of structurally diverse data. Based on unique NMR structural descriptors, the new SDAR modeling method complements the existing SAR techniques, providing an independent estimator that can increase confidence in a structure- activity assessment. When modeling was applied to hazardous environmental chemicals, it was found that up to 20% of them may be substrates and up to 10% of them may be inhibitors of the CYP3A4 and CYP2D6 isoforms. The developed models provide a rare opportunity for the environmental health branch of the public health service to extrapolate to hazardous chemicals directly from human clinical data. Therefore, the pharmacological and environmental health branches are both expected to benefit from these reported models.
引用
收藏
页码:3383 / 3406
页数:24
相关论文
共 40 条
  • [1] Modeling Chemical Interaction Profiles: II. Molecular Docking, Spectral Data-Activity Relationship, and Structure-Activity Relationship Models for Potent and Weak Inhibitors of Cytochrome P450 CYP3A4 Isozyme
    Tie, Yunfeng
    McPhail, Brooks
    Hong, Huixiao
    Pearce, Bruce A.
    Schnackenberg, Laura K.
    Ge, Weigong
    Buzatu, Dan A.
    Wilkes, Jon G.
    Fuscoe, James C.
    Tong, Weida
    Fowler, Bruce A.
    Beger, Richard D.
    Demchuk, Eugene
    MOLECULES, 2012, 17 (03) : 3407 - 3460
  • [2] Cytochrome b5 Is a Major Determinant of Human Cytochrome P450 CYP2D6 and CYP3A4 Activity In Vivo
    Henderson, Colin J.
    McLaughlin, Lesley A.
    Scheer, Nico
    Stanley, Lesley A.
    Wolf, C. Roland
    MOLECULAR PHARMACOLOGY, 2015, 87 (04) : 733 - 739
  • [3] In vitro comparative inhibition profiles of major human drug metabolising cytochrome p450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
    Transon, C
    Leemann, T
    Dayer, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (03) : 209 - 215
  • [4] Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice
    Felmlee, Melanie A.
    Lon, Hoi-Kei
    Gonzalez, Frank J.
    Yu, Ai-Ming
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) : 435 - 441
  • [5] INVOLVEMENT OF CYP2D6, CYP3A4, AND OTHER CYTOCHROME-P-450 ISOZYMES IN N-DEALKYLATION REACTIONS
    COUTTS, RT
    SU, P
    BAKER, GB
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1994, 31 (04) : 177 - 186
  • [6] In vitro effects and in silico analysis of newly synthetized pyrrole derivatives on the activity of different isoforms of Cytochrome P450 CYP1A2, CYP2D6 and CYP3A4
    Angelov, Borislav
    Mateev, Emilio
    Georgieva, Maya
    Tzankova, Virginia
    Kondeva-Burdina, Magdalena
    PHARMACIA, 2022, 69 (04) : 1013 - 1017
  • [7] Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region
    Liu, Hongtao
    Xu, Lianhong
    Hui, Hon
    Vivian, Randy
    Callebaut, Christian
    Murray, Bernard P.
    Hong, Allen
    Lee, Melody S.
    Tsai, Luong K.
    Chau, Jennifer K.
    Stray, Kirsten M.
    Cannizzaro, Carina
    Choi, You-Chul
    Rhodes, Gerry R.
    Desai, Manoj C.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (03) : 989 - 994
  • [8] Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity
    Lim, Sharoen Yu Ming
    Azidin, Athira Rafhana Binti
    Ung, Yee Tze
    Al-Shagga, Mustafa
    Alshawsh, Mohammed Abdullah
    Mohamed, Zahurin
    Ong, Chin Eng
    Pan, Yan
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (03) : 423 - 431
  • [9] Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity
    Sharoen Yu Ming Lim
    Athira Rafhana Binti Azidin
    Yee Tze Ung
    Mustafa Al-Shagga
    Mohammed Abdullah Alshawsh
    Zahurin Mohamed
    Chin Eng Ong
    Yan Pan
    European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44 : 423 - 431
  • [10] Inhibition of cytochrome P450 monooxygenase-catalyzed oxylipin formation by flavonoids: Evaluation of structure-activity relationship towards CYP4F2-selective inhibitors
    Kampschulte, Nadja
    Berking, Tim
    Celik, Ibrahim E.
    Kirsch, Stefan F.
    Schebb, Nils Helge
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 238